Boadie Dunlop, MD, discusses COMP360 dosing-day monitoring, treatment resistance, and where psilocybin may fit among existing TRD options.
Boadie Dunlop, MSC
Advertisement
Boadie Dunlop, MSC, professor and chair of psychiatry and health behavior at the Medical College of Georgia at Augusta University.
Articles by Boadie Dunlop, MSC
New 26-week COMP006 data show durable MADRS improvement after 2 COMP360 psilocybin doses in treatment-resistant depression, Dunlop explains.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Daily Inhaled TPIP Improved PAH Measures at 12 Months in OLE
2
FIND-CKD Trial Poses Finerenone as a "Third Pillar" for Nondiabetic CKD
3
What New 26-Week COMP006 Data Mean for TRD, With Boadie Dunlop, MD
4
FDA Approves Enlicitide for LDL-C Lowering in Adults With Hypercholesterolemia
5